Repurposing Generic Intravenous Racemic Ketamine from Anesthesia to Treatment-Resistant Depression in Resource-Limited Settings: A Scoping Review
Year: 2026
Type: study-registration
Abstract: Background & Purpose: Treatment-Resistant Depression (TRD) is a significant clinical challenge. While patented nasal esketamine is cost-prohibitive for public healthcare systems, generic intravenous (IV) racemic ketamine is already widely available in hospital operating rooms at a fraction of the cost, though its use remains largely restricted to anesthesia. This scoping review maps global evidence on IV racemic ketamine for TRD, focusing specifically on clinical efficacy to support hospital administrators in evaluating its feasibility for public health adoption. Core Research Focus: - What are the reported clinical response and remission rates of IV racemic ketamine for unipolar and bipolar TRD? Methodology (PCC Framework & PubMed Search): Following Joanna Briggs Institute (JBI) methodology, eligibility criteria are structured using the PCC framework: - Population (P): Patients of any age with unipolar or bipolar Treatment-Resistant Depression (TRD). - Concept (C): Repurposed generic intravenous (IV) racemic ketamine and its clinical efficacy outcomes. - Context (C): Global clinical settings where evaluating low-cost generic alternatives is clinically relevant. To maintain a focused scope, the literature search will be conducted exclusively via PubMed. Studies will be screened to extract clinical response/remission metrics, demonstrating the therapeutic viability of repurposing existing hospital ketamine stock.
Source: Open Science Framework
Author: Hussein Ali Jihad
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7235324682
Cites:
Cited by:
Related to:
